Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Gastroesophageal reflux disease (GERD) considered to be associated with mucosal damages in
the esophagus and heartburn, which may sometimes interfere with daily activities due likely
to reflux of acid gastric contents. While most of the patients given the diagnosis of GERD do
not exhibit endoscopically obvious impairment in esophageal mucous membrane, they have
subjective symptoms of non-erosive GERD including heartburn. But no drug has been launched in
Japan, which targets non-erosive GERD. This study will examine the efficacy and safety of
famotidine in subjects with non-erosive GERD.